5-methyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one | 4926-18-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 5-methyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one
• 英文别名: 5-methyl-2H-[1,2,4]triazolo[4,3-a]pyridin-3-one
• CAS: 4926-18-5
• 化学式: C₇H₇N₃O
• 分子量: 149.152
• InChiKey: NEJANSQSQQBYLO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  44.7
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-methyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one 以60%的产率得到
  参考文献：
  名称：

  POTTS K. T.; BRUGEL E. G.; DUNLAP W. C., TETRAHEDRON , 1977, NO 11, 1247-1251

  摘要：

  DOI：
• 作为产物：
  描述：

  2-甲基-6-氯吡啶 以33%的产率得到5-methyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one
  参考文献：
  名称：

  Anti-psychotic agents

  摘要：

  2-[4-[4-芳基哌嗪-1-基]丁基]-1,2,4-三唑并[4,3-a]吡啶-3(2H)-酮是抗精神病药物。

  公开号：

  US04465683A1

文献信息

• The Base-Promoted Annulation of 2-Hydrazinyl Pyridine and CO₂ toward Triazolones
  作者：Xiaopeng Wu、Song Sun、Bingbing Wang、Jiang Cheng

  DOI：10.1002/adsc.201700869

  日期：2017.11.10

  A base‐promoted annulation of 2‐hydrazinyl pyridine and atmospheric pressure of CO2 has been developed in the presence of silane as reducing reagent, affording a series of triazolones in moderate to excellent yields. CO2 served as a carbonyl source in this transfomation. Moreover, benzamidrazones also worked well under this procedure. Thus, it represents a green, sustainable and straightforward pathway

  在硅烷作为还原剂存在下，开发了碱促进的2-肼基吡啶环化反应和大气压下的CO 2，可提供中等至极好的收率的三唑酮系列。在这种转化过程中，CO 2用作羰基来源。此外，苯并dra唑酮在该程序下也能很好地工作。因此，它代表了访问三唑酮框架的绿色，可持续和直接途径。
• Antidepressant agent
  申请人：Mead Johnson & Company

  公开号：US04254124A1

  公开（公告）日：1981-03-03

  2-[3-[4-[3-(Trifluoromethyl)phenyl]-1-piperazinyl]propyl]-1,2,4-triazolo[4, 3-a]pyridin-3(2H)-one and its pharmaceutically acceptable acid addition salts are antidepressant agents.

  2-[3-[4-[3-(三氟甲基)苯基]-1-哌嗪基]丙基]-1,2,4-三唑并[4,3-a]吡啶-3(2H)-酮及其药用可接受的酸盐是抗抑郁药物。
• WNT SIGNALING INHIBITOR
  申请人：KYOWA HAKKO KIRIN CO., LTD.

  公开号：US20160168125A1

  公开（公告）日：2016-06-16

  A Wnt signaling inhibitor which comprises, as an active ingredient, a fused-ring heterocyclic compound represented by the following formula (IA) or a pharmaceutically acceptable salt thereof, and the like are provided: (wherein, n 1A represents 0 or 1; n 2A and n 3A may be the same or different, and each represents 1 or 2; R OA represents optionally substituted aryl or the like; R 2A represents a hydrogen atom or the like; R 3A represents an optionally substituted aromatic heterocyclic group or the like; X 1A , X 2A , X 3A and X 4A each represent CH or the like; Y 1A represents CH 2 or the like; Y 2A represents N or the like; and L A represents CH 2 or the like).

  提供一种Wnt信号抑制剂，其包括以下式（IA）所表示的融合环杂环化合物作为活性成分或其药学上可接受的盐等：（其中，n1A表示0或1；n2A和n3A可以相同也可以不同，每个表示1或2；ROA表示可选择地取代的芳基或类似物；R2A表示氢原子或类似物；R3A表示可选择地取代的芳香杂环基或类似物；X1A、X2A、X3A和X4A各自表示CH或类似物；Y1A表示CH2或类似物；Y2A表示N或类似物；LA表示CH2或类似物）。
• CAP/ENDO DUAL INHIBITORS AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE
  申请人：F. Hoffmann-La Roche AG

  公开号：US20160002227A1

  公开（公告）日：2016-01-07

  The present invention relates to a compound having the general formula (V), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, codrug, cocrystal, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which are useful in treating, ameloriating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.

  本发明涉及具有一般式（V）的化合物，可选地以药学上可接受的盐、溶剂合物、多型体、共药、共晶、前药、互变异构体、拉克米酸盐、对映体或二对映体或其混合物的形式存在，用于治疗、缓解或预防病毒性疾病。此外，还披露了具体的联合疗法。
• Triazolo (4,3-a)pyridin-3(2H)-ones, process for their preparation and pharmaceutical compositions containing them
  申请人：Bristol-Myers Company

  公开号：EP0025603A1

  公开（公告）日：1981-03-25

  Tyriazo)o[4,3-a]pyridin-3(2H)-ones represented by the formula: wherein RI is hydrogen or lower alkyl having 1 to 4 carbon atoms and located in the 5, 6, 7, or 8 positions of the tri- azolo[4,3-a]pyridin-3(2H)-one ring, and R2 is hydrogen, or it is a substituent located in the 2, 3, or 4 position of the phenyl ring and selected from the group consisting of lower alkyl having 1 to 4 carbon atoms, lower alkoxy having 1 to 4 carbon atoms, halogen or trifluoromethyl and the pharmaceutically acceptable acid addition salts thereof, which exhibit excellent anti-psychotic activity and are useful as anti-psychotic agents. The invention also provides a process for the preparation of said compounds, a pharmaceutical composition comprising at least one of said compounds and use of said compounds in the treatment of psychotic conditions.

  式所代表的噻唑并[4,3-a]吡啶-3(2H)-酮： 其中 RI 是氢或位于三唑并[4,3-a]吡啶-3(2H)-酮环的 5、6、7 或 8 位的具有 1 至 4 个碳原子的低级烷基，以及 R2 是氢，或者是位于苯环 2、3 或 4 位的取代基，该取代基可从具有 1 至 4 个碳原子的低级烷基、具有 1 至 4 个碳原子的低级烷氧基、卤素或三氟甲基组成的组中选出。 及其药学上可接受的酸加成盐，它们具有优异的抗精神病活性，可用作抗精神病药物。本发明还提供了制备所述化合物的工艺、包含至少一种所述化合物的药物组合物以及所述化合物在治疗精神病方面的用途。